Oxolife, the Women’s Reproductive Health R&D biotech, has been awarded with a 2.4M€ grant from the Spanish Science and Innovation Ministry (PlanEstatal de Investigación Científica) to develop a new treatment for infertility related to polycystic ovarian syndrome (PCOS). Oxolife, CataloniaBio & HealthTech member, in collaboration with Cordoba’s University, plans to progress in the next 2 years from preclinical stages to a phase II clinical trial in PCOS patients.

PCOS is an endocrine disease affecting upto 13% of women of childbearing age, causing infertility in most of them (>70%). Unfortunately, current medical management, based on restoring ovulatory function or metabolic status, cannot meet the expectations of women and couples, since more than 60% cannot become pregnant with available treatments.

Oxolife is developing a unique new treatment designed to restore the reproductive system in a single intervention, with the potential to overcome the limitations of current strategies in PCOS.

Ignasi Canals, Oxolife’s CSO, states, “This grant speeds up a promising line of research that targets ovarian dysfunction, endometrial receptivity, and the metabolic status, tackling the syndrome in a holistic way. We’re encouraged to provide a solution for women and couples suffering from PCOS, in a short period”

Oxolife, with its pipeline, achieves a prominent position within the Women's Reproductive Health biotech sector. Oxolife’s CEO and CMO, Agnes Arbat, declares: “With a pharmaceutical compound that increases embryo implantation already in phase II human trials, and a unique late-stage preclinical asset for infertility related to PCOS, we cover the most prevalent causes of female infertility. We’re now in a privileged position, enlarging the pipeline and transferring projects from early stages to late development of consistent and convenient products, bringing new solutions to patients”.